Enumeral

Enumeral Biomedical Holdings, Inc.
Company typePublic
OTCQB: ENUM
IndustryBiotechnology
FoundedDecember 11, 2009 (2009-12-11)
DefunctJanuary 29, 2018 (2018-01-29)
FateAssets sold to Xoma Corporation during bankruptcy
Headquarters
Cambridge, Massachusetts
,
United States
Key people
  • John Rydzewski (Chairman)
  • Kevin G. Sarney (interim CEO, 2018): Signatures 
ProductsMonoclonal antibodies targeting immune checkpoint proteins
Number of employees
10 (2017)
Websitewww.enumeral.com

Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates. The company filed for Chapter 11 bankruptcy and arranged to sell its assets to Xoma Corporation in January 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.